The Department of Psychiatry at Yale University School of Medicine requests a second renewal of this 5 year post-doctoral research training grant for intervention and services research in treatment, rehabilitation and prevention of severe mental disorders. This training grant is responsive to the behavioral translational research priorities of NIMH and trains fellows for two to three years who focus on research that aims at relieving the burden of mental illness, the top priority of NIMH. The renewal would continue to support 4 post-doctoral fellows with clinical training (physicians or psychologists) seeking research training for careers in academic medicine.
The specific aims of the training program are: 1) To provide physician and clinically trained psychologists with training in translational research methods, biostatistics, the responsible conduct of scientific research, and intervention development to become independent researchers and clinician scientists. 2) To provide these post-doctoral trainees with experience in all aspects of conducting such research, from initial project conceptualization and design, through implementation and data analysis to manuscript preparation and oral presentation of results. 3) To provide a mentored and closely supervised opportunity for trainees to develop, implement and complete all phases of an independent clinical research project. 4) To support trainees in submission of independent research initiatives including career awards, NARSAD and other young investigator awards, and NIMH R21's, R34's & R01's. The Executive Committee is comprised of 7 senior researchers who are full professors and have access to extensive research and training resources at both the VA Connecticut Healthcare System and Yale School of Medicine, 9 program faculty who are Associate Professors or higher, and a number of ad hoc mentors who are available for individual training plans. Major research programs include the VA's Northeast Program Evaluation Center, the VA's MIRECC in dual diagnosis, the VA/Yale Learning Based Recovery Center, the Early Intervention and Prevention of Psychosis Program at Yale, and the Yale Program for Recovery and Community Health. The Chair of the Department of Psychiatry and the VA Chief of Psychiatry serve as faculty, and there is cross-over with other relevant institutions at Yale including the School of Epidemiology and Public Health. Past recruitment has yielded a large number of highly competitive candidates including underrepresented minorities, and all who have been offered positions have accepted with 18% of fellows being underrepresented minorities. Of the six graduates during the current funding period, four received career development awards, one went on to another fellowship, and one became Assistant Professor with independent funding at another major medical center. Of the 13 fellows who have completed, all remain in academic medicine. This track record reflects the support and resources fellows receive in moving toward independent research careers.

Public Health Relevance

This proposal requests a second renewal of this 5 year post-doctoral research training grant for intervention and services research in treatment, rehabilitation and prevention of severe mental disorders. This training grant focuses on research that aims at relieving the burden of mental illness, the top priority of NIMH. The renewal would continue to support 4 post-doctoral fellows with clinical training (physicians or psychologists) seeking research training for careers in academic medicine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Institutional National Research Service Award (T32)
Project #
5T32MH062994-14
Application #
8853953
Study Section
Special Emphasis Panel (ZMH1)
Program Officer
Hill, Lauren D
Project Start
2001-04-01
Project End
2016-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
14
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Wilkinson, Samuel T; Kiselycznyk, Carly; Banasr, Mounira et al. (2018) Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord 241:514-518
Wilkinson, Samuel T; Ballard, Elizabeth D; Bloch, Michael H et al. (2018) The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry 175:150-158
Wilkinson, Samuel T; Agbese, Edeanya; Leslie, Douglas L et al. (2018) Identifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans. Psychiatr Serv 69:542-548
Davidson, Charlie A; Lesser, Rebecca; Parente, Lori T et al. (2018) Psychometrics of social cognitive measures for psychosis treatment research. Schizophr Res 193:51-57
Wilkinson, Samuel T; Katz, Rachel B; Toprak, Mesut et al. (2018) Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. J Clin Psychiatry 79:
van Schalkwyk, Gerrit I; Wilkinson, Samuel T; Davidson, Larry et al. (2018) Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. J Affect Disord 227:11-16
Wilkinson, Samuel T; Rosenheck, Robert A (2017) Electroconvulsive Therapy at a Veterans Health Administration Medical Center. J ECT 33:249-252
Adams, Thomas G; Bloch, Michael H; Pittenger, Christopher (2017) Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder. J Clin Psychopharmacol 37:269-271
Wilkinson, Samuel T; Sanacora, Gerard; Bloch, Michael H (2017) Hippocampal volume changes following electroconvulsive therapy: a systematic review and meta-analysis. Biol Psychiatry Cogn Neurosci Neuroimaging 2:327-335
Wilkinson, Samuel T; Wright, DaShaun; Fasula, Madonna K et al. (2017) Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression. Psychother Psychosom 86:162-167

Showing the most recent 10 out of 52 publications